Hot Products
| Catalog No. | Information |
| CFN98507 | Ginkgolic acid C13:0 Ginkgolic acid C13:0 has a wide antimicrobial spectrum against E.coli and bacillus subtilis who are bacterias, and penicillium, penicillum purpurogenum, penicillium camemberti and aspergillus niger who are fungis, and the MIC of it against E.coli, bacillus subtilis and penicillium is 7.5, 15, 25 mg/mL seperately. It is a natural anticariogenic agent in that it exhibits antimicrobial activity against S. mutans and suppresses the specific virulence factors associated with its cariogenicity. Ginkgolic acid C13:0 exhibits the high α-glucosidase inhibitory activity; Ginkgolic acid C13:0 represents a new kind of molluscicide agent , it has a pronounced effect on snail mitochondria with gross ultrastructural changes. |
| CFN90339 | Ginkgolic acid C15:0 Reference standards. |
| CFN90161 | Ginkgolic acid C15:1 Ginkgolic acid C15:1 has antibacterial, antiparasitic, and anti-cancer activities, it can suppress lung cancer invasion and migration through the inhibition of PI3K/Akt/mTOR signaling pathway. |
| CFN98508 | Ginkgolic acid C17:1 Ginkgolic acid C17:1 can significantly inhibit enterohemorrhagic Escherichia coli O157:H7(EHEC) biofilm formation on the surfaces of polystyrene and glass, and on nylon membranes. |
| CFN99638 | Ginkgolide A Ginkgolide A is a platelet-activating factor antagonist, it can inhibit the neurotoxicity of prions or amyloid-beta1-42, may be relevant treatments for prion or Alzheimer's diseases.Ginkgolide A has neuroprotective, and anxiolytic-like effects, it is widely used for the treatment of cardiovascular diseases and diabetic vascular complications, which might be achieved through regulating the STAT3-mediated pathway. |
| CFN99640 | Ginkgolide B Ginkgolide B has potent neuroprotective, anti-arrhythmias, anti-inflammatory and anti-apoptotic effects, it might be a promising drug on inhibiting platelet function and reducing inflammation in atherosclerosis.Ginkgolide B retards the proliferation and development of mouse embryonic stem cells (ESCs) and blastocysts in vitro and causes developmental injury in vivo. |
| CFN99639 | Ginkgolide C Ginkgolide C is a potent inhibitor of collagen-stimulated platelet aggregation, it may increase intracellular cAMP and cGMP production and MMP-9 activity, inhibit intracellular Ca(2+) mobilization and TXA(2) production. Ginkgolide C has anti-adipogenic and ameliorating Alzheimer disease effects; it also can increase△LVP significantly,enhances the myocardial systolic and diastolic function of rats,but has no significant effect on HR while it shows inotropic activity. |
| CFN99149 | Ginkgolide J Ginkgolide J has neuroprotective activity, it can prevent A beta(1-42) induced inhibition of long-term potentiation in the CA1 region of mouse hippocampal slices, it is also capable of inhibiting cell death of rodent hippocampal neurons caused by A beta(1-42). Ginkgolide J can inhibit platelet aggregation induced by ADP or PAF. |
| CFN91009 | Ginkgolide K Ginkgolide K exerts anti-oxidative stress and neuroprotective effect on ischemic stroke, it has potentially anti- Parkinson's disease activity, it can promote the clearance of A53T mutation alpha-synuclein in SH-SY5Y cells. Ginkgolide K promotes angiogenesis after ischemia stroke through increasing the expression of HIF-1α/VEGF via JAK2/STAT3 pathway, it promotes astrocyte proliferation and migration after oxygen-glucose deprivation via inducing protective autophagy through the AMPK/mTOR/ULK1 signaling pathway. Ginkgolide K can inhibit PAF-induced platelet aggregation and improve nerve injury after cerebral ischemia-reperfusion. |
| CFN99756 | Ginsenoside Compound K Ginsenoside compound K (C-K) is a metabolite of the protopanaxadiol-type saponins of Panax ginseng C.A. Meyer, has long been used to treat against the development of cancer, inflammation, allergies, and diabetes; C-K acts as a unique HUVEC migration inhibitor by regulating MMP expression, as well as the activity of SPHK1 and its related sphingolipid metabolites. C-K exhibits anti-inflammatory effects by reducing iNOS and COX-2, C-K exhibits an inhibition against the activity of CYP2C9 and CYP2A6 in human liver microsomes with IC50s of 32.0±3.6 μM and 63.6±4.2 μM, respectively. C-K promotes Aβ clearance by enhancing autophagy via the mTOR signaling pathway in primary astrocytes. |
